Product Images Riluzole

This is a product manufactured by Quinn Pharmaceuticals for which contact information is provided. The product was manufactured by Standard Chem. & Pharm. Co., Ltd. in Taiwan.*

The description is for Riluzole 50mg tablets. Each tablet contains 50g of USP and should be taken orally every 12 hours. The prescription should be taken as directed. There is a caution to keep the medication fresh and protect it from high temperatures. There is further information about the manufacturer and contact details.*

This is a comparison of side effects in two groups of people. One group was given Riluzole Tablets of 50mg, twice daily (N=313), and the other group was given a placebo (N=320). The table lists various side effects experienced by participants in both groups, such as asthenia, nausea, hypertension, decreased lung function, and abdominal pain. The percentage of people experiencing each side effect is listed.*

This is a table showing pharmacokinetic parameters of riluzole, a drug used for the treatment of amyotrophic lateral sclerosis (ALS). The drug has an oral bioavailability of approximately 60% and is linear over a dose range of 25 mg to 100 mg. The absorption of the drug is affected by food, resulting in a 20% increase in AUC and a 45% increase in Cmax when taken with a high-fat meal. The drug is highly protein-bound (96%), mainly to albumin and lipoproteins. The elimination half-life is approximately 12 hours, and there is high interindividual variability in the clearance of riluzole, potentially attributable to variability in CYP1A2. The primary elimination pathway for the drug is through the urine (80%), with 2% unchanged riluzole. The drug is metabolized through oxidation and direct and sequential glucuronidation, with at least 88% of the dose being metabolized. Some metabolites of the drug appear pharmacologically active in vitro, but the clinical implications are not known.*